Atox Bio Announces Dosing of the First Subject in Its Phase 1 Study of AB103  
9/14/2010 12:30:20 PM

REHOVOT, Israel--(BUSINESS WIRE)--Atox Bio Inc. today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.